The era of "theoretical" longevity is over. As of February 2026, we have officially entered the age of human application. Aris Sterling breaks down the monumental shift in the Information Theory of Aging, moving beyond the initial Harvard "ICE" mouse studies into the first-ever FDA-cleared human clinical trials for partial cellular reprogramming. We analyze how companies like Life Biosciences and NewLimit are now using inducible gene therapy (ER-100) to treat age-related blindness by "rebooting" retinal cells in living patients. This episode explores the 2025 breakthroughs in mRNA-based epigenetic resets, which allow for precise, temporary "software updates" to your biology without the risk of permanent genomic alteration. If you are still relying on 2023 data, you are missing the transition from "slowing down" to "active reversal." We deliver the three tactical moves to optimize your biological data integrity in the age of clinical rejuvenation.

Citation Sources:

1. Lifespan Research Institute (Feb 2026): "First Human Cellular Reprogramming Trial Cleared by the FDA: The Era of ER-100."

2. Nature Aging (2025): "The 2025 Geroscience Roundup: From Biomarkers to Clinically Deployable Interoperable Phenotypes."

3. Journal of Gene Medicine (Jan 2026): "Synthetic DNA and mRNA-based Epigenetic Programming: The New Frontier in Tissue Restoration."